University of Cambridge

New Report from Gemserv and tado° Shows Smart Thermostats Most Cost Effective and Scalable Way to Decarbonise Homes in the EU’s Green Deal Renovation Wave

Thursday, October 21, 2021 - 9:00am

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    To realise these goals and reduce CO2 emissions, approximately 600 billion has been reserved in the EUs Green Deal funds2.
  • On average a smart thermostat from tado saves 22% of energy used in homes across Europe, based on data provided by over 1 million connected thermostats3.
  • According to tado, the cost for implementing smart thermostats in all European homes would be approximately 40 billion, or 6.67% of the total cost allocated for the European Green Deal.
  • As the only cross-manufacturer platform, tado Smart Thermostats and services connect with any kind of heating or cooling system.

NATASHA PRASAD JOINS SWORD HEALTH AS CHIEF EXPERIENCE OFFICER

Tuesday, October 19, 2021 - 1:00pm

NEW YORK, NY, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SWORD Health, the most clinically advanced virtual musculoskeletal (MSK) care provider, has named Natasha Prasad as its Chief Experience Officer.

Key Points: 
  • NEW YORK, NY, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SWORD Health, the most clinically advanced virtual musculoskeletal (MSK) care provider, has named Natasha Prasad as its Chief Experience Officer.
  • Prasad will help SWORD deliver a best-in-class member experience across our rapidly growing patient population.
  • As Chief Experience Officer, Prasad will unify all touchpoints with the member to deliver a cohesive, engaging experience that will continue to improve SWORDs already industry-leading clinical outcomes.
  • Prasads addition to the team follows Pavle Stojkovic, Chief People Officer, and Carla Newell, Chief Legal & Risk Officer.

Inivata Announces Clinical Collaboration with Princess Margaret Cancer Center for the use of its Liquid Biopsy Assays

Tuesday, October 19, 2021 - 12:00pm

Research Triangle Park, NC, USA and Cambridge, UK, 19 October 2021 -- Inivata, a leader in liquid biopsy, today announced a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata’s liquid biopsy assays, InVisionFirst®-Lung and RaDaR™ in two separate studies.

Key Points: 
  • Research Triangle Park, NC, USA and Cambridge, UK, 19 October 2021 -- Inivata, a leader in liquid biopsy, today announced a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivatas liquid biopsy assays, InVisionFirst-Lung and RaDaR in two separate studies.
  • The first phase, DETECT, will screen 360 early-stage lung cancer patients to assess the rate of pre- and post-operative ctDNA levels using RaDaR.
  • Dr. Natasha Leighl, Lung Site Lead, Medical Oncology, Princess Margaret Cancer Center, said: Liquid biopsy technologies have the potential to transform cancer treatment, getting patients to the right treatment faster and increasing the chances of a cure.
  • Inivatas InVision liquid biopsy platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse.

US headquartered Ignitho names former Mindtree exec as CTO; to exponentially grow its Data Engineering and Cloud Capabilities

Monday, October 18, 2021 - 1:00pm

Ashin brings to Ignitho two decades of technology leadership experience and was with Mindtree for close to a decade playing key tech leadership roles.

Key Points: 
  • Ashin brings to Ignitho two decades of technology leadership experience and was with Mindtree for close to a decade playing key tech leadership roles.
  • His area of specialization include Big Data, Cloud and Emerging Technologies; with expertise in designing and implementing digital enterprise solutions.
  • Ashin will drive Ignitho's Data, Cloud and Digital Engineering areas as the company gets ready to cross $12 million in revenue by 2023.
  • Ignitho, a Nuivio Ventures company, delivers Digital Engineering solutions, taking Enterprises from ambition to success in the Data Led, Cloud Enabled, Digital Economy.

China Int'l 'Internet +' Competition Boosts College Students' Enthusiasm for Innovation, Entrepreneurship

Thursday, October 14, 2021 - 7:37pm

NANCHANG, China, Oct. 14, 2021 (GLOBE NEWSWIRE) -- The ongoing 7th China International "Internet +" College Students Innovation and Entrepreneurship Competitionhas largely boosted college students' enthusiasm for creativity, and provided an education exchange platform of innovation and entrepreneurship, according to competition organizer Chinese Ministry of Education.

Key Points: 
  • NANCHANG, China, Oct. 14, 2021 (GLOBE NEWSWIRE) -- The ongoing 7th China International "Internet +" College Students Innovation and Entrepreneurship Competitionhas largely boosted college students' enthusiasm for creativity, and provided an education exchange platform of innovation and entrepreneurship, according to competition organizer Chinese Ministry of Education.
  • The China International "Internet +" College Students Innovation and Entrepreneurship Competition is a master competition that has been held annually for seven consecutive years since it was inaugurated in 2015.
  • The "National College Students Innovation and Entrepreneurship Training Plan" has become a basic training project for all college students, which has helped the emerging of innovation and entrepreneurship talents.
  • The China International College Students' "Internet+" Innovation and Entrepreneurship Competition has become the world's largest innovation and entrepreneurship competition for college students.

Now Shipping Worldwide: SenseGlove Nova, Haptic Force-Feedback Gloves For Professional VR/AR Training And Research

Thursday, October 14, 2021 - 6:00pm

DELFT, Netherlands, Oct. 14, 2021 /PRNewswire-PRWeb/ -- SenseGlove , a leading developer of force and haptic feedback gloves, today announced it has begun worldwide shipping of SenseGlove Nova , a new version of haptic force-feedback gloves designed specifically for professional VR training and research purposes.

Key Points: 
  • DELFT, Netherlands, Oct. 14, 2021 /PRNewswire-PRWeb/ -- SenseGlove , a leading developer of force and haptic feedback gloves, today announced it has begun worldwide shipping of SenseGlove Nova , a new version of haptic force-feedback gloves designed specifically for professional VR training and research purposes.
  • "Easy-to-use and accessible haptic gloves represent a huge step forward for the VR training industry," said Gijs den Butter, CEO of SenseGlove.
  • Bulk orders of 10 or more Nova gloves are available at a discounted rate of $3,500 per set of gloves.
  • SenseGlove develops force and haptic feedback gloves that enable professionals to feel and interact with virtual objects for VR training and research purposes.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Sprott Names Two New Independent Directors

Wednesday, October 13, 2021 - 9:01pm

TORONTO and NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE/TSX: SII) (Sprott or the Company) announced today the appointment of Barbara Connolly Keady and Catherine Raw to the Companys board of directors.

Key Points: 
  • TORONTO and NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE/TSX: SII) (Sprott or the Company) announced today the appointment of Barbara Connolly Keady and Catherine Raw to the Companys board of directors.
  • We are delighted to welcome Barbara and Catherine to the board, said Ron Dewhurst, Chairman of the Sprott board of directors.
  • Sprott is fortunate to have attracted directors of Barbara and Catherines caliber, and we will benefit from their global financial and extractive industry experience, said Peter Grosskopf, CEO of Sprott.
  • She has served as a Director on the board of Sprott Focus Trust (FUND) since 2015 and is also a Director on the boards of the Sprott Gold Equity Fund, the Sprott Gold Miners ETF, and the Sprott Junior Gold Miners ETF.